Therapeutic Purpose of Nilverm

Nilverm is an anthelmintic medication, commonly used in veterinary medicine to address internal parasitic infections. The active ingredient, levamisole, works by interfering with the neuromuscular system of specific parasites, leading to their paralysis and subsequent elimination from the host's body.

Main Uses

Nilverm is primarily indicated for the treatment and control of various gastrointestinal and pulmonary nematode infections. It is effective against both adult and immature stages of many roundworm species. Common applications include:

• Gastrointestinal Roundworms: It targets several types of worms that inhabit the stomach and intestines, such as Haemonchus, Ostertagia, Trichostrongylus, and Nematodirus species.
• Lungworms: The medication is frequently used to treat infections caused by lungworms, such as Dictyocaulus species, which can cause respiratory distress in livestock.

Benefits and Action

The medication offers a broad-spectrum approach to parasite management, which is essential for maintaining the health and productivity of animals. The primary benefits of Nilverm include:

• Rapid Action: Levamisole is absorbed quickly, allowing for a fast onset of action against the target parasites.
• Broad Efficacy: It is effective against a wide range of nematode species, making it a versatile option for routine parasite control programs.
• Dual Mode of Action: In addition to its anthelmintic properties, levamisole is known to have immunomodulatory effects in some contexts, potentially supporting the host's immune response while the parasitic burden is reduced.

Nilverm, which contains the active ingredient Levamisole, has different regulatory statuses for human and animal use across major global health authorities.

Official Eligibility and Contraindications

Classification	Rule (Official Regulatory Basis)
Human Use Status	Withdrawn from the market in the United States and Canada; remains authorized in some EU and WHO-listed countries for specific infections.
Contraindicated	Individuals with known allergic hypersensitivity to levamisole or its components. Specific animal species, such as dogs and horses (for the veterinary product).
Restricted/Caution	Patients with a predisposition to hematologic abnormalities (e.g., agranulocytosis) or an active infection. Animals that are severely debilitated or stressed.

Specific Population Rules

• Pregnancy and Lactation: Use in humans during pregnancy is typically restricted to when the benefit clearly outweighs the potential risk. It is contraindicated in lactating dairy animals and is generally not recommended for use in human breastfeeding mothers.
• Age: The product is generally approved for adults and children where a human-use product is authorized, but specific dosage for children is based on weight.
• Conditions: Use requires caution in patients with significant renal or hepatic impairment, as noted in some official labeling.

Regulatory documentation largely defines eligibility by excluding those with a known allergy or a history of specific blood cell disorders, while its primary licensed status in many regions is restricted to use in specific livestock.

Interactions with other medicines and products

Nilverm, which contains the active substance Levamisole, has specific officially documented interaction patterns that are based on its regulatory status, including its primary veterinary use and historical human oncology use. These patterns are categorized based on their official classification in regulatory documents.

---

Documented Interaction Restrictions

Classification	Interacting Substance	Official Restriction Basis
Contraindicated	Alcohol (Ethanol)	Risk of severe disulfiram-like reaction (pharmacodynamic effect).
Contraindicated	Organophosphorus Compounds	Prohibited due to potential for fatal, additive toxicity.

---

Exposure-Modifying and Pharmacodynamic Effects

Co-administration with Levamisole alters the systemic exposure or effect of several agents, which necessitates specific regulatory constraints:

• Warfarin: Levamisole increases the anticoagulant effect of Warfarin, classified as a clinically significant interaction.
• Phenytoin: Co-administration may increase the toxicity of Phenytoin, indicating altered clearance or increased systemic exposure.
• Ivermectin: Levamisole is documented to increase the systemic bioavailability ( C max and AUC) of Ivermectin.
• Albendazole: Conversely, Levamisole reduces the systemic bioavailability ( C max and AUC) of Albendazole.

Furthermore, in regimens utilizing Fluorouracil, the timing of subsequent doses is governed by regulatory deferral rules tied to blood count monitoring, reflecting a specific co-administration constraint.

Nilverm Mechanism of Action: How It Works

---

Agonism at Nematode Nicotinic Receptors

The mechanism involves Levamisole acting as an agonist that binds to the nicotinic acetylcholine receptors ( nAChRs) located on the muscle cells of nematodes. This molecular interaction initiates a sustained activation that causes the associated ion channels to remain open.

---

Sustained Muscle Depolarization and Spastic Paralysis

The continuous receptor activation causes irreversible depolarization of the muscle cell membrane, resulting in a state of sustained muscle contraction. This sustained stimulation results in spastic paralysis across the nematode's body, causing the loss of the worm's capacity for coordinated movement and adherence to tissues.

---

Motility Disruption and Target Selectivity

The paralysis-driven disruption of the worm's motility renders the organism unable to resist forces from surrounding tissues, facilitating its passage via normal intestinal peristaltic movements. This process relies on the drug's high target selectivity, demonstrating greater binding affinity for the nematode's nAChRs than for the host organism's corresponding neuromuscular signaling pathways.

How to Use Nilverm (Levamisole) — Official Administration Guidelines

Official instructions for Nilverm, a Levamisole-based veterinary drug, establish a protocol focused on precise dosing and administration to livestock. Adherence to these guidelines is required for ensuring efficacy and observing public health requirements.

---

Administration Scope

Attribute	Instruction Summary
Route of Administration	Oral (Drench, Soluble Powder in Feed/Water) or Subcutaneous Injection.
Standard Dosing Schedule	The dose must be calculated precisely based on live body weight, typically targeting 7.5 mg Levamisole base per kilogram (kg) body weight as the standard therapeutic rate.
Frequency	Typically a single administration. Repeat treatment must be determined by farm management protocols or veterinary guidance.
Preparation Requirements	Ready-to-use drenches require no mixing. Soluble powder must be reconstituted in water or thoroughly mixed into a small portion of feed to ensure complete consumption.

---

Procedural and Safety Requirements

Procedural Steps:

1. Weighing: Determine the weight of the animal (or the heaviest in the group) to calculate the maximum required dose.
2. Dose Calculation: Calculate the volume or mass required to meet the 7.5 mg/kg standard.
3. Equipment Check: Calibrate or check the accuracy of the drenching or injection equipment before and during administration.
4. Administration: Deliver the calculated dose via the approved route (oral or subcutaneous).

Use Constraints:

The most critical constraint is the observation of the Withholding Period (WHP) for meat and milk. Animals must not be slaughtered for human consumption and milk must not be taken for human use until the specific time period stipulated on the product label has elapsed after the final dose. This protocol ensures drug residues are minimized before food products enter the human supply chain.

Research Evidence / Overview of Studies for Nilverm (Levamisole)

---

Evidence for Use in Treating Parasitic Worm Infections

Research exploring Levamisole in the context of parasitic worm infections, such as those caused by roundworms (Ascaris lumbricoides) and hookworms, is primarily based on short-term controlled trials and multicenter evaluations. These studies often evaluated Levamisole as a comparator in trials involving a placebo or other medications used to treat parasitic infections. Researchers primarily monitored outcomes related to parasite clearance, such as measuring the decrease in the number of eggs found in patient samples (egg reduction rate) and whether the parasite was completely cleared (cure rate).

Studies reported measurements for the egg reduction rate and cure rate that were observed in the study populations, particularly in infections caused by Ascaris lumbricoides. Findings describe patterns observed in the studies related to short-term changes. Data for long-term outcomes regarding the sustained absence of infection or the rate of re-infection beyond six months are limited in the core evidence. Research continues to examine potential changes in measured outcomes over time, representing an area of research uncertainty.

---

Evidence for Use as Adjuvant Therapy in Colon Cancer

Research for Levamisole when it was evaluated as an adjuvant treatment (given after initial therapy) for colon cancer involves large-scale Randomized Clinical Trials (RCTs) with long observation periods. These trials specifically examined Levamisole in combination with the chemotherapy drug 5-fluorouracil following surgery for Stage III colon cancer. The main outcomes studied included Overall Survival (OS) and Disease-Free Survival (DFS), which are patient-reported outcomes describing the time until death or cancer recurrence.

Early large intergroup trials reported measured outcomes related to survival and recurrence rates when the combination regimen was evaluated. However, later clinical trials described that measured survival outcomes were variable and did not consistently align with patterns observed in earlier research. Research findings related to its evaluation in Stage II colon cancer are uncertain because most large trials concentrated on Stage III disease.

---

What Is Still Uncertain About Nilverm Research

Evidence highlights what is known, but also what is still uncertain. Data remains insufficient for studies involving all potential parasitic species, as research is ongoing for certain types of infection. The follow-up durations were limited in many of the parasitic infection studies, providing limited information about long-term patterns of change. For the cancer indication, comparative evidence is lacking to fully establish its place against the advanced regimens currently being studied.

Key Studies & References

1. Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication - Review of Randomized Trials
2. PRAC starts safety review of levamisole, a medicine used to treat parasitic worm infections (Regulatory Context/Safety Concerns affecting evidence interpretation)

Common questions about Nilverm (FAQ)

Q: Is Nilverm the same type of medication as [similar-sounding drug]?

Official product information indicates that the active substance in Nilverm is Levamisole. This substance belongs to the anthelmintic class, meaning it is classified as an anti-worm agent. Levamisole is also noted for having immunomodulatory properties, which refers to its secondary ability to help support the body's general response to infection or challenge.

Q: What are the most common side effects people report when first starting Nilverm?

Studies and official information on Levamisole's human use indicate that temporary and commonly reported side effects may include nausea, vomiting, abdominal pain, and diarrhea. Effects related to the nervous system, such as dizziness and headache, have also been reported. These effects are typically temporary.

Q: Does Nilverm need to be taken with food, or does it matter?

According to regulatory-cited patient education materials, there are no known interactions between the active substance, Levamisole, and any food. Official guidance does not generally specify a requirement for taking the medication with or without food.

Q: Can Nilverm affect a person's energy level or cause drowsiness?

Official reports on adverse events have included instances of drowsiness and irritability, suggesting potential effects on the central nervous system (CNS). If a patient experiences unusual changes in energy level or noticeable drowsiness, official guidance indicates that advice should be sought from a qualified healthcare provider.

Q: Are there any specific dietary restrictions or things to avoid while taking Nilverm?

Official regulatory documents state that alcohol is contraindicated due to the risk of a severe disulfiram-like reaction. This classification means alcohol consumption must be avoided while the active substance Levamisole is in use. No specific food interactions are noted in the official materials.

Q: What kind of symptoms or conditions is Nilverm not approved to treat?

Official regulatory documents define who cannot use the drug by stating it is contraindicated in individuals with a known hypersensitivity (allergy) to the drug or its components. It is also contraindicated for individuals with certain pre-existing blood disorders. The specific uses of Nilverm are defined by its approved indications.

Q: Is Nilverm available as a generic version, and is it the same?

Nilverm is a brand name for the active substance Levamisole Hydrochloride. Regulatory systems identify drugs by this chemical name, and generic versions, if authorized and available, contain the identical active substance, Levamisole Hydrochloride.

Q: Does Nilverm have any potential effects on mood or anxiety levels?

Regulatory-cited data suggests the potential for effects on the nervous system, which has included reports of changes such as anxiety and irritability. This is noted in studies examining the substance's effects.

Q: Does Nilverm need to be stored in the refrigerator?

Official product labels generally recommend storing the product below 30°C (Room Temperature). The guidance advises storage in a cool, dry place and protection from direct sunlight, rather than specifically requiring refrigeration.

Q: Does Nilverm show up on standard drug screening tests?

Specific laboratory tests are available in diagnostic settings to detect the active substance, Levamisole, in biological samples such as urine specimens. These tests are used for analytical and diagnostic purposes and are not part of routine screening panels.

Q: What should a patient do if they experience a mild side effect from Nilverm?

Official patient guidance advises that a qualified healthcare provider should be contacted immediately if symptoms persist or in all cases of doubt. The guidance further states that a healthcare provider should be contacted for any bothersome symptom, such as an unrelieved rash or persistent nausea.

Q: Does the packaging of Nilverm contain an ingredient that causes allergies?

The official regulatory documentation indicates that use of the drug is contraindicated for patients with a known hypersensitivity (allergy) to Levamisole or its components. This means that non-active ingredients in the formulation may pose a risk to allergic individuals.

Q: How long does Nilverm stay in the body after the last dose is taken?

Official pharmacokinetics data for the active substance, Levamisole, reports an estimated plasma elimination half-life of 3–4 hours. The elimination half-life is the time required for the amount of the substance in the plasma to decrease by 50%, with excretion primarily occurring through the kidneys.

Official Storage and Disposal Requirements

The storage and disposal profile for Nilverm (Levamisole Hydrochloride) is defined by strict regulatory guidelines to ensure product stability, user safety, and environmental protection.

Storage Requirement	Official Guidance
Access & Environment	Store locked up in a cool, dry place and a well-ventilated area.
Container & Protection	Keep the container tightly closed and in a properly labeled container. Protect from direct sunlight.

Handling and Disposal

Official documents mandate specific handling practices, including wearing protective equipment and ensuring proper ventilation when handling the substance (especially in powder form) to prevent inhalation. Disposal of the product and its containers must occur through an approved waste disposal plant, strictly following local and national regulations. To protect the environment, the substance must not be released into surface water, ground water, or drains, and any spills must be contained and managed appropriately.